---
title: "The controllable nuclear fusion sector opened high, China Energy Engineering has three consecutive limit-ups"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249673024.md"
description: "The controllable nuclear fusion sector opened high, with ZHEFU, DONGFANG ELEC, and CH ENERGY ENG achieving three consecutive trading limits, while Zheneng Electric Power, CNEC, and China National Nuclear Technology Corporation also opened high"
datetime: "2025-07-23T01:31:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249673024.md)
  - [en](https://longbridge.com/en/news/249673024.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249673024.md)
generator: "portal-rs"
---

# The controllable nuclear fusion sector opened high, China Energy Engineering has three consecutive limit-ups

The controllable nuclear fusion sector opened high, with ZHEFU, DONGFANG ELEC, and CH ENERGY ENG achieving three consecutive trading limits, while Zheneng Electric Power, CNEC, and China National Nuclear Technology Corporation also opened high

### Related Stocks

- [002266.CN](https://longbridge.com/en/quote/002266.CN.md)
- [600875.CN](https://longbridge.com/en/quote/600875.CN.md)
- [01072.HK](https://longbridge.com/en/quote/01072.HK.md)
- [601868.CN](https://longbridge.com/en/quote/601868.CN.md)
- [03996.HK](https://longbridge.com/en/quote/03996.HK.md)
- [601611.CN](https://longbridge.com/en/quote/601611.CN.md)

## Related News & Research

- [CHINA COAL  1H26 Net Profit Up 11.8% YoY to RMB8.19B; Div. RMB0.184](https://longbridge.com/en/news/296591654.md)
- [Apollo Atomics wants to make nuclear power cheaper by shrinking an overlooked part](https://longbridge.com/en/news/296502139.md)
- [Chery's robot unit Aimoga prepares for IPO, targets 10,000 deliveries next year](https://longbridge.com/en/news/296357521.md)
- [CMOC Last Soars 5%+; Interim Profit Surges 86%, Revenue Hits Record High; Interim DPS Resumed at RMB0.095](https://longbridge.com/en/news/296423052.md)
- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**